is an investigational, orally delivered biologic currently in clinical development for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) . Developed by Sorriso Pharmaceuticals, it represents a potential paradigm shift in how advanced therapies are administered to patients with chronic gastrointestinal inflammation. What is SOR102?
:
Localized activity confirmed by minimal systemic drug levels in the blood. Why it Matters: Breaking the "Therapeutic Ceiling" sor102
:
Recent Phase 1b clinical data, published in journals like The Lancet Gastroenterology & Hepatology , highlight three critical advantages of SOR102: is an investigational